Clinical Trials Directory

Trials / Sponsors / Anthera Pharmaceuticals

Anthera Pharmaceuticals

Industry · 25 registered clinical trials.

StatusTrialPhaseStarted
UnknownRESULT: Reliable, Emergent Solution Using Liprotamase Treatment
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Phase 32017-04-28
CompletedEASY: Extended Access to Sollpura Over Years
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Phase 42016-09-01
TerminatedCHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Eryt
Systemic Lupus Erythematosus
Phase 32016-06-01
CompletedSIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Phase 32016-06-01
WithdrawnMONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in S
Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura
Phase 2 / Phase 32015-12-01
WithdrawnCHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Ery
Systemic Lupus Erythematosus
Phase 32015-12-01
CompletedSOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosi
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Phase 32015-06-01
WithdrawnBIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Phase 22014-12-01
WithdrawnBRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
IgA Nephropathy
Phase 32014-10-01
CompletedBRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
IgA Nephropathy
Phase 2 / Phase 32013-06-01
CompletedCHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Ery
Systemic Lupus Erythematosus
Phase 32013-02-01
TerminatedA Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
Sickle Cell Disease, Vaso-occlusive Crisis
Phase 22012-02-01
CompletedStudy to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects
Healthy Volunteers
Phase 12011-06-01
TerminatedA Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function
Renal Impairment
Phase 12011-06-01
CompletedA Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
Systemic Lupus Erythematosus
Phase 22011-04-01
CompletedPEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Sys
Systemic Lupus Erythematosus
Phase 22010-07-01
TerminatedVISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronar
Acute Coronary Syndrome
Phase 32010-05-01
CompletedFRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes
Acute Coronary Syndrome
Phase 22008-07-01
TerminatedPhase III ALTU-135 CP Safety Trial
Exocrine Pancreatic Insufficiency
Phase 32007-12-01
CompletedPLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease
Coronary Artery Disease
Phase 22007-09-01
CompletedOpen-Label Phase III Long-Term Safety Trial of Liprotamase
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Phase 32007-06-01
CompletedLiprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Phase 32007-05-01
CompletedPLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease
Coronary Artery Disease (CAD)
Phase 22007-04-01
CompletedIMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome
Phase 22006-12-01
CompletedOral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
Cystic Fibrosis, Pancreatic Insufficiency
Phase 22004-06-01